NCT04399148已完成不适用
Influence of Antipruritics on the Dermal Blood Flow Response After a Histamine Skin Prick as Well as After the Topical Application of Cinnamaldehyde and Capsaicin
适应症
干预措施
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 13
- 试验地点
- 1
- 主要终点
- Change in dermal blood flow induced by histamine skin pricks, compared to baseline and placebo following the administration of different antipruritic drugs
研究概览
简要总结
In order to validate the accuracy and reliability of the histamine skin prick model for histaminergic itch and vasodilation, the dermal blood flow response induced by a histamine skin prick will be evaluated after the administration of certain antipruritics. Besides, the influence of these antipruritics on the dermal blood flow response induced by the topical application of cinnamaldehyde and capsaicin will be evaluated. Changes in dermal blood flow will be measured with laser speckle contrast imaging.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Basic Science
- 盲法
- Double (Participant, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 45 Years（Adult）
- 性别
- Male
- 接受健康志愿者
- 是
入选标准
- •Subject is a white male ≥ 18 and ≤ 45 years of age at the time of screening
- •Subject is a nonsmoker for at least 6 months prior to the study start
- •Subject has a body mass index ≥ 18 and ≤ 30 kg/m2
- •Subject has a clear increase in histamine-induced dermal blood flow; Subject has an increase in capsaicin- and cinnamaldehyde-induced dermal blood flow of at least 100% as determined during the screening visit
- •Subject is judged to be in good health on the basis of medical history, physical examination and vital signs
- •Subject understands the procedures and agrees to comply with them for the entire length of the study by giving written informed consent.
排除标准
- •Subject has excessive hair growth on the volar surface of the forearm
- •Subject has a past or present history of diffuse dermatological conditions including eczema, scleroderma, psoriasis, urticaria, dermatographism and dermatitis
- •Subject has any abnormality on the skin of the forearm, possibly interfering with the study assessments including tattoos, keloids, tumors, ulcers, burns, flaps and grafts;
- •Subject cannot avoid excessive tanning (any exposure to sunlight or a tanning bed which would cause a sunburn reaction) throughout the study and cannot cover the forearms 24 hours before and after each study visit
- •Subject currently uses lotions, oils, depilatory preparations, makeup or other topical treatments on the arms and on a regular basis which cannot be discontinued for the duration of the study; subject has used any topical treatments within 7 days of the start of the study
- •Subject has a past or present history of (symptomatic) asthma
- •Subject has a history of severe allergic reactions to food or drugs or adverse experiences of a serious nature related to the administration of either a marketed or investigational drug, including histamine, cinnamaldehyde, capsaicin, desloratadine, ketotifen or aprepitant
- •Subject currently uses any prescription or nonprescription drugs on a regular basis which cannot be discontinued for the duration of the study; subject has used any prescription or nonprescription medication within 14 days of the start of the study
- •Subject is a habitual and heavy consumer of coffee or caffeinated beverages (more than approximately 4 cups of tea, coffee or cola per day) at the time of the study. Subjects who have reduced their consumption to ≤ 4 cups per day at least 1 week prior to enrollment may participate; Subjects who cannot refrain from caffeinated beverages 24 hours before the study visit
- •Subject is unable to refrain from drinking alcohol 24 hours prior to histamine application, is currently a regular user (including "recreational use") of any illicit drugs, or has a history of drug (including alcohol) abuse. A drug screen will include amphetamines/ methamphetamines, methylenedioxymethamphetamine, benzodiazepines, barbiturates, cocaine, cannabis, tricyclic antidepressants, methadone and opiates
- •Subject cannot refrain from being around second hand smoke 24 hours prior to histamine application or uses nicotine-containing products. Ex-smokers should have ceased smoking at least 6 months prior to screening
- •Subject has any of the following vital sign measurements at screening: heart rate ≤ 40 or ≥ 100 beats/min, diastolic blood pressure ≤ 50 or ≥ 89 mmHg and/or systolic Blood Pressure ≤ 90 or ≥ 139 mmHg
- •Subject has been involved in testing an investigational drug in another clinical study within the last 4 weeks or 5 half-lives
- •Subject has evidence of a clinically significant active infection, fever of 38°C or above at the time of the study visits
- •Subject has a history or current cardiovascular, respiratory, hepatic, renal, gastrointestinal or neurological disorders capable of significantly altering the absorption, metabolism or elimination of drugs
- •Subject is in a situation or has a condition, which, in the opinion of the investigator, may interfere with safe and optimal participation in the study
- •Subject has a history of any illness or disorder, which, in the opinion of the investigator, might confound the results of the study.
研究组 & 干预措施
Sequence 1
Experimental
Desloratadine - Aprepitant - Ketotifen
干预措施: Desloratadine 5 mg (Drug)
Sequence 1
Experimental
Desloratadine - Aprepitant - Ketotifen
干预措施: Aprepitant 125 mg (Drug)
Sequence 1
Experimental
Desloratadine - Aprepitant - Ketotifen
干预措施: Ketotifen 1 MG (Drug)
Sequence 2
Experimental
Aprepitant - Ketotifen - Desloratadine
干预措施: Desloratadine 5 mg (Drug)
Sequence 2
Experimental
Aprepitant - Ketotifen - Desloratadine
干预措施: Aprepitant 125 mg (Drug)
Sequence 2
Experimental
Aprepitant - Ketotifen - Desloratadine
干预措施: Ketotifen 1 MG (Drug)
Sequence 3
Experimental
Ketotifen - Desloratadine - Aprepitant
干预措施: Desloratadine 5 mg (Drug)
Sequence 3
Experimental
Ketotifen - Desloratadine - Aprepitant
干预措施: Aprepitant 125 mg (Drug)
Sequence 3
Experimental
Ketotifen - Desloratadine - Aprepitant
干预措施: Ketotifen 1 MG (Drug)
结局指标
主要结局
Change in dermal blood flow induced by histamine skin pricks, compared to baseline and placebo following the administration of different antipruritic drugs
时间窗: The dermal blood flow will be assessed before (baseline) and every 10 minutes during the hour following the skin pricks
次要结局
- Change in dermal blood flow induced by topical application of cinnamaldehyde and capsaicin, compared to baseline and placebo following the administration of different antipruritic drugs(The dermal blood flow will be assessed before (baseline) and every 10 minutes during the hour following application)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
Influence of H1-antihistamines on the Dermal Blood Flow Response to Histamine, Cinnamaldehyde and Capsaicin.PruritusNCT04399525Universitaire Ziekenhuizen KU Leuven12
已完成
不适用
Dermal Blood Flow Response to Escalating Doses of Histamine, Administered by a Skin PrickPruritusNCT04399213Universitaire Ziekenhuizen KU Leuven13
已完成
不适用
A study of skin responses to histaminedelicate skinhyper-reactive skin10014982NL-OMON41203Philips Research24
尚未招募
不适用
Study of skin prick test using with histamine as positive controlAllergic diseases including bronchial asthma, food allergy, atopic dermatitis and allergic thinitisJPRN-UMIN000026982Ehime University Hospital250
已完成
不适用
Validation of Laser Doppler Flowmetry to Identify Allergic Rhinitis Patients With Pharmacogenetic Alterations in Histamine MetabolismAllergic RhinitisNCT00362999Children's Mercy Hospital Kansas City74